Hartman Institute for Therapeutic Organ Regeneration

Human pluripotent-stem-cell-derived organoids for drug discovery and evaluation.

TitleHuman pluripotent-stem-cell-derived organoids for drug discovery and evaluation.
Publication TypeJournal Article
Year of Publication2023
AuthorsJ Vandana J, Manrique C, Lacko LA, Chen S
JournalCell Stem Cell
Volume30
Issue5
Pagination571-591
Date Published2023 May 04
ISSN1875-9777
KeywordsDrug Discovery, Drug Evaluation, Preclinical, Humans, Organoids, Pluripotent Stem Cells
Abstract

<p>Human pluripotent stem cells (hPSCs) and three-dimensional organoids have ushered in a new era for disease modeling and drug discovery. Over the past decade, significant progress has been in deriving functional organoids from hPSCs, which have been applied to recapitulate disease phenotypes. In addition, these advancements have extended the application of hPSCs and organoids for drug screening and clinical-trial safety evaluations. This review provides an overview of the achievements and challenges in using hPSC-derived organoids to conduct relevant high-throughput, high-contentscreens and drug evaluation. These studies have greatly enhanced our knowledge and toolbox for precision medicine.</p>

DOI10.1016/j.stem.2023.04.011
Alternate JournalCell Stem Cell
PubMed ID37146581
PubMed Central IDPMC10775018
Grant ListDP3 DK111907 / DK / NIDDK NIH HHS / United States
R01 DK130454 / DK / NIDDK NIH HHS / United States
R01 DK119667 / DK / NIDDK NIH HHS / United States
R01 DK124463 / DK / NIDDK NIH HHS / United States
U01 DK127777 / DK / NIDDK NIH HHS / United States
R01 DK116075 / DK / NIDDK NIH HHS / United States

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065